Running Title: The role of caspase-10 in Taxol induced apoptosis
INTRODUCTION
Taxol (paclitaxel) is a potent anticancer agent known to promote microtubule 4 involved in apoptosis: (a) the mitochondrion-initiated pathway, and (b) the cell surface death receptors pathway (28) . In the mitochondrial pathway, cytochrome c, certain caspases, apoptosis-inducing factor (AIF), Smac/DIABLO, an inhibitor of apoptosis protein (IAP)-binding protein, and other apoptosis-inducing factors are released from the intramembrane space to the cytosol (29) . Once released, cytochrome c and dATP bind to apoptotic proteinase activating factor-1 (Apaf-1), and this complex, along with adenine nucleotides, promotes procaspase-9 autoactivation (30), which in turn activates caspases-2, -3, -6, -8, and -10 (31-33). In the death receptor-mediated apoptosis pathway (e.g., Fas/Fas ligand interaction and cell death), caspase-8 is an initiator caspase that can activate the downstream caspases including caspase-3. Active caspase-8 also cleaves a pro-apoptotic Bcl-2 family member, Bid, and the truncated Bid induces mitochondrial cytochrome c release (30, 34) , thereby linking the two pathways.
After activation, both caspase-8 and caspase-9 activate caspase-3, which in turn cleaves other caspases and many cellular proteins including fodrin, protein kinase C (PKC), poly (ADP-ribose) polymerase (PARP), gelsolin and DNA fragmentation factor-45 (DFF45) (28, 33) . A third pathway also has been recently identified (35) . In this pathway, Bid is cleaved downstream of the point of Bcl-2 action, catalyzed by caspase-3, upstream of caspase-8 activation, and acts as a potential feedback loop for amplification of apoptosis-associated release of cytochrome c from the mitochondria.
Our data revealed that Taxol induces FADD-dependent apoptosis in CCRF-HSB-2 cells independently of the death receptors. Moreover, for the first time, we found that Taxol triggers apoptosis primarily through activation of caspase-10 and the signaling pathway downstream of this caspase, including caspase-6 and -3 activation, or dnFADD/pcDNA3 using SuperFect reagent (Qiagent, Valencia, CA) as described by the manufacturer. The transfectants were then selected by adding 1 mg/ml G418 to the growth media. The dnFADD/pcDNA3 plasmid was kindly provided by Dr. Claudius Vincenz (University of Michigan, Ann Arbor, MI).
Isolation of Cytosolic Fraction for Detecting Cytochrome c. CCRF-HSB-2
cells (approximately 2 x 10 7 ) were incubated with or without Taxol for 48 hr and harvested by centrifugation at 1,800 x g for 10 min at 4ºC. Cells were then washed once in ice-cold PBS and suspended in 5X volume of ice-cold buffer (20 mM HEPES [pH 7.5], 10 mM KCl, 1.5 mM MgCl 2, 1 mM EDTA, 1 mM sucrose). After incubation on ice for 15 min, the cells were mechanically disrupted with a Dounce homogenizer.
Unbroken cells and nuclei were centrifuged at 1800 x g for 5 min at 4ºC. The 9 supernatant, which contained mitochondria, was subjected to further centrifugation at 20,000 x g at 4ºC for 30 min to pellet the mitochondrial fraction. The resulting supernatant was filtered through a Microcon YM-100 filter. The flow-through (i.e., cytosolic fraction) was mixed with ice-cold acetone and proteins were precipitated at -20ºC for several hours. After centrifugation at 14,000 x g for 30 min at 4ºC, the protein pellet was dissolved in SDS sample buffer, heated to 95ºC for 3 min, and subjected to Western blotting analysis for cytochrome c. Results presented in Fig. 2 clearly illustrate that the inhibitors of caspase-3 or caspase-8
Preparation of Cytosol Fractions from Cells and
partially and the inhibitors of caspase-6 or caspase-10 almost totally inhibited Taxolinduced apoptosis. However, the inhibitor of caspase-9, Z-LEHD-FMK, did not prevent Taxol-induced apoptosis (Fig. 2 ). To confirm these data, another caspase-9
inhibitor, LEHD-CHO, was used, and it also had no effect on apoptosis, revealing that caspase-9 does not play a role during Taxol-triggered apoptosis. Furthermore, our
Western blot analysis shows that caspase-9 was not activated by Taxol (Fig. 4C ).
Collectively, the data shown in Fig. 2 revealed that the initiator caspase-10 and the executioner caspase-6 are essential for triggering Taxol-induced apoptosis. However, none of the caspase inhibitors used affected necrosis. We also assessed the effects of the cathepsin B inhibitor Z-FA-fmk and the cathepsin L inhibitor Z-FF-fmk, and found that these inhibitors did not affect Taxol-induced apoptosis (data not shown).
To determine whether Taxol treatment causes activation of caspases, we performed Western blotting of the executioner caspases (caspases-3 and -6) and initiator caspases (caspases-8, -9, and -10) using antibodies capable of recognizing the pro-forms and activated forms of these caspases. Western blot analysis of caspase- 3 13 was performed using a rabbit polyclonal antibody produced to recombinant human caspase-3, known to recognize both the 32 kDa procaspase-3, as well as the 17 kDa and 11 kDa activated forms of this caspase. As shown in Fig. 3A , treatment of the cells with 0.1, 0.5, and 1 µM Taxol for 48 hr increased the cleavage of procaspase-3 to its 17 kDa and 11 active forms in these cells (Fig. 3A) . Moreover, treating the cells with the caspase-10 inhibitor Z-AEVD-FMK and Taxol as described in Experimental procedures prevented the processing of procaspase-3 to its active species, but it was not fully processed and was presented as an inactive 24 kDa intermediate form (39) Furthermore, the caspase-10 inhibitor Z-AEVD-FMK also totally inhibited cleavage of procaspase-10 to its active forms, revealing autocatalytic activation of caspase-10 by Taxol (Fig. 4B, panel b) .
We further determined whether Taxol treatment causes cleavage and activation of caspase-9, using a polyclonal antibody known to recognize both the 46 kDa procaspase-9 as well as the 37 kDa active form. Western blot analysis shown in Fig. 4C revealed that this antibody recognizes the proform of this caspase to the same extent in both untreated and Taxol-treated CCRF-HSB-2 cells (Fig. 4C) . As a positive control, we treated CCRF-HSB-2 cells with etoposide (VP-16) and detected the 37 kDa active form of this caspase (Fig. 4C) . Therefore, Taxol-induced apoptosis is independent of caspase-9 activation in CCRF-HSB-2 cells.
To determine the sequential activation of caspases during Taxol-induced apoptosis and explore whether caspase-10 activation occurs prior to that of the other 
Taxol-Induced Apoptosis Is Associated with Decreased Mitochondrial
Membrane Potential (∆Ψm). To determine whether Taxol induces apoptosis through the mitochondrion-initiated pathway, CCRF-HSB-2 cells were treated with 0.1, 0.5, and 1 µM Taxol for 48 hr, and decreases in mitochondrial membrane potential (∆ψm)
were assessed by flow cytometry as described in Experimental Procedures (Fig. 9A-D) .
Taxol-Induced Apoptosis Is Independent of Increased Reactive Oxygen
Species Production. It is known that increased ROS are likely to act as signaling intermediates that are involved in the signal transduction pathways of apoptosis (38, (44) (45) (46) (47) . Therefore, we measured increased production of ROS during Taxol that Taxol-induced apoptosis in these cells is ROS-independent (Fig. 10B ). To determine whether Taxol treatment induces p53 and p21 WAF-1/CIP-1 during apoptosis, CCRF-HSB-2 cells were treated with 0.1, 0.5, and 1 µM Taxol for 48 hr and levels of these proteins were detected by Western blotting. Our data clearly showed that these proteins were not induced during this process (data not shown).
DISCUSSION
Taxol is a highly active anticancer drug that triggers apoptosis in wide spectrum of cancer cells by caspase-dependent and -independent apoptosis mechanisms (12-14).
However, the exact mechanism and signaling pathways involved in Taxol-induced apoptosis are not well established. In the present study, we investigated the molecular mechanism of Taxol-induced apoptosis in CCRF-HSB-2 cells with respect to death receptors, mitochondrial apoptotic signaling pathways, and the involvement of caspase cascades.
Apoptosis induced by different stimuli, such as death ligands, chemotherapeutic drugs or ionizing irradiation, and leads to the activation of caspases (48) . In this report, we demonstrated that caspases-3, -6, -8, and -10 were activated during apoptosis induced by various concentrations of Taxol. Our data clearly showed that the initiator caspase-10 and the executioner caspase-6 are essential for triggering Taxol-induced apoptosis. Furthermore, caspase-8 plays a lesser role than caspases-6 and -10 in this process.
Activation of the caspase-9/Apaf1/cytochrome c apoptosome in the mitochondrial-dependent apoptotic pathway leads, in turn, to caspase-3 activation (30) . It is known that increased reactive oxygen species (ROS) are likely to act as signaling intermediates involved in the signal transduction pathways of apoptosis (38, (45) (46) (47) . However, our results revealed that Taxol-induced apoptosis was independent of ROS formation. These results are supported by a recent report showing that while
Taxol induces ROS formation in hepatoma cells, Taxol-triggered apoptosis in these cells is independent of ROS formation (72) .
Taxol-induced apoptosis is cell cycle dependent (73, 74) , and at the low dose, it induces both p53 (73, 74) and p21 (74) . Moreover, Taxol triggers p53-dependent apoptosis in some cell lines (73, 74) and p53-independent apoptosis in others (75) .
Although CCRF-HSB-2 cells express wild-type homozygous p53 (Ogretmen and Safa, unpublished data), our results showed that treatment with Taxol did not affect the expression of p53 in these cells, revealing that Taxol-induced apoptosis is independent of p53 in these cells. Similarly, Taxol did not induce p21 in these cells, but in a control experiment, doxorubicin very significantly induced this protein, indicating that Taxolinduced apoptosis is independent of p21 WAF-1/CIP-1 .
Based on the results in this report, we have proposed the signaling pathway of Taxol-induced apoptosis in CCRF-HSB-2 cells (Fig. 11) . In this signaling pathway, Taxol primarily induces autocatalytic activation of caspase-10, which in turn activates caspases-6 and -3. While caspase-8 is also autocatalytically activated and activates Smac/DIABLO release from the mitochondria, cytosolic fractions were prepared and used as described in the Experimental procedures. However, it appears that these factors either play no role or minimal roles in the induction of apoptosis by this anticancer agent. 
